A systematic review of bevacizumab efficacy in breast cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Angiogenesis is a key component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for the treatment of cancer. We systematically describe phase II and III clinical trials of bevacizumab for the treatment of breast cancer.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Treat. Rev.

Title: Cancer treatment reviews

ISSN (Electronic): 1532-1967

ISSN (Print): 0305-7372

Publication date (Electronic): Sep 2014

Volume: 40

Issue: 8

Affiliations

[1 ] Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: iben.kumler@regionh.dk.

[2 ] Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: olegrummedal@gmail.com.

[3 ] Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: dorte.nielsen.01@regionh.dk.

Article

Publisher Item ID: S0305-7372(14)00091-7

DOI: 10.1016/j.ctrv.2014.05.006

PubMed ID: 24909311

SO-VID: 00d57f9f-3e83-4f8e-bf0b-dabfd3511ed9

History

Keywords: Angiogenesis,Bevacizumab,Breast cancer,VEGF

Data availability:

Keywords: Angiogenesis, Bevacizumab, Breast cancer, VEGF

Comments

Comment on this article

scite_

Cited by 13

See all cited by